

21 August 2024



Italy Tender Win for Xprecia Prime

Universal Biosensors, Inc. (ASX: UBI) is pleased to announce it has received notification its distribution partner in Italy has won another tender with Xprecia Prime. The tender is to supply two Health Authorities in the north of Italy and includes approximately 45,000+ strips per annum and 53 Xprecia Prime devices for a term of 3 years and is valued at more than \$450,000.

This is UBI's second tender win in Italy for Xprecia Prime in recent months.

End

Announcement authorised by the Board of Directors of Universal Biosensors, Inc.

For further information contact:

John Sharman
Chief Executive Officer
+61 (0) 414 440 680

About Universal Biosensors

Universal Biosensors, founded in 2001, specialises in the design and development of electrochemical cells (strips) used in conjunction with point of use devices that are used in various industries such as healthcare (point of care), wine, food, and agriculture. UBI's ambition is to build a multi product stable of biosensors in large markets which generate ongoing revenue streams. For additional information regarding Universal Biosensors, Inc., refer to: <http://www.universalbiosensors.com>.

About Xprecia Prime™

The Xprecia Prime™ Coagulation Analyzer is Universal Biosensors second generation, new and improved coagulation monitoring device. Xprecia Prime™ fits into your palm; is portable, accurate and easy to use. The device is designed for fast and reliable prothrombin time (PT) results displayed in seconds and International Normalised Ratio (INR). It is used to monitor the dosage of vitamin K antagonists in patients to ensure its safety and efficacy. Dangerous bleeding events can occur if the ideal dosage of the drug is exceeded, while if the dosage is lower than required the patient is at risk of thrombosis. The prothrombin time (PT) test allows physicians to appropriately adjust the patient's dose of the drug to compensate for any diet and lifestyle changes. Globally, approximately 10 million patients are taking warfarin, and over 300 million PT/INR tests are conducted annually to monitor the safe and effective dosage of anticoagulants, representing a major market opportunity for Xprecia Prime™. For additional information visit: <https://www.universalbiosensors.com/products/xprecia/>

Forward-Looking Statements

The statements contained in this release that are not purely historical are forward-looking statements within the meaning of the US Securities Exchange Act of 1934. Forward-looking statements in this release include statements regarding our expectations, beliefs, hopes, intentions or strategies. All forward-looking statements included in this release are based upon information available to us as of the date hereof, and we assume no obligation to update any such forward-looking statement as a result of new information, future events or otherwise. Our actual results could differ materially from our current expectations. We cannot assure you when, if at all, the proposals outlined in this release will occur, and the terms of any such proposal are subject to change. Factors that could cause or contribute to such differences include, but are not limited to, factors and risks disclosed from time to time in reports filed with the SEC.